Ubs Asset Management Americas Inc Allakos Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$2.13 - $5.55 $27,690 - $72,150	13,000 Added 16.22%	93,127 $211,000
Q1 2023 May 15, 2023	BUY	$4.3 - $8.27 $49,355 - $94,923	11,478 Added 16.72%	80,127 $356,000
Q4 2022 Feb 14, 2023	BUY	$5.66 - $8.42 $388,553 - $578,024	68,649 New	68,649 $578,000
Q2 2022 Aug 12, 2022	SELL	$2.6 - $6.14 $115,492 - $272,738	-44,420 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.08 - $9.81 $79,791 - $154,085	15,707 Added 54.7%	44,420 $253,000
Q4 2021 Feb 14, 2022	SELL	$8.55 - $111.89 $54,018 - $706,921	-6,318 Reduced 18.04%	28,713 $281,000
Q3 2021 Nov 15, 2021	BUY	$76.53 - $110.43 $58,545 - $84,478	765 Added 2.23%	35,031 $3.71 Million
Q2 2021 Aug 16, 2021	BUY	$85.37 - $114.1 $715,315 - $956,043	8,379 Added 32.37%	34,266 $2.93 Million
Q1 2021 May 14, 2021	BUY	$109.73 - $153.66 $406,001 - $568,542	3,700 Added 16.68%	25,887 $2.97 Million
Q4 2020 Mar 01, 2021	BUY	$79.58 - $152.45 $111,412 - $213,429	1,400 Added 6.73%	22,187 $3.11 Million
Q3 2020 Nov 13, 2020	BUY	$66.43 - $90.99 $2,989 - $4,094	45 Added 0.22%	20,787 $1.69 Million
Q2 2020 Aug 14, 2020	BUY	$44.04 - $80.69 $85,129 - $155,973	1,933 Added 10.28%	20,742 $1.49 Million
Q1 2020 May 15, 2020	SELL	$44.49 - $93.39 $82,840 - $173,892	-1,862 Reduced 9.01%	18,809 $836,000
Q4 2019 Feb 14, 2020	BUY	$66.49 - $137.73 $145,147 - $300,664	2,183 Added 11.81%	20,671 $1.97 Million
Q3 2019 Nov 14, 2019	BUY	$31.0 - $89.73 $359,228 - $1.04 Million	11,588 Added 167.94%	18,488 $1.45 Million
Q2 2019 Aug 15, 2019	BUY	$36.0 - $44.73 $39,600 - $49,203	1,100 Added 18.97%	6,900 $0
Q1 2019 May 14, 2019	BUY	$33.79 - $51.99 $195,982 - $301,542	5,800 New	5,800 $0

Others Institutions Holding ALLK

# of Institutions

Shares Held

66.9M

Call Options Held

47.1K

Put Options Held

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $22.9M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account